Inhibition of the complement anaphylatoxin activities in the central nervous system disorders

2021 ◽  
Vol 21 (2) ◽  
pp. 37-52
Author(s):  
Kseniya A. Nekrasova ◽  
Alexander M. Ischenko ◽  
Alexander V. Trofimov

The review is devoted to inhibition of the complement anaphylatoxin activities in diseases of the central nervous system. Here we present epidemiological data on the prevalence of cerebrovascular diseases, in particular, ischemic stroke and craniocerebral trauma. The mechanisms of complement activation and complement-mediated pathology in the central nervous system are considered in detail. Clinical data confirming the role of the complement system in the pathogenesis of stroke and of traumatic brain injury secondary injury are presented. We also summarize the results of in vivo specific activity studies of the complement anaphylatoxin inhibitors using animal models of stroke and traumatic brain injury. Briefly described is the present state of the art in developing drugs that target the effector compounds of the complement cascade.

1978 ◽  
Vol 56 (3) ◽  
pp. 535-538 ◽  
Author(s):  
S. W. Tang ◽  
H. C. Stancer ◽  
J. J. Warsh

A new strategy for measurement of brain catecholamines was tested in an animal model. [3H]Norepinephrine was infused intravenously in rabbits to label the peripheral norepinephrine pools. The specific activity of urinary 3-methoxy-4-hydroxymandelic acid was consistently higher than that for 3-methoxy-4-hydroxyphenylglycol (MHPG). Central sympathectomy with 6-hydroxydopamine abolished this difference. Using the formula we propose, it is estimated that 30–50% of urinary MHPG originates from the central nervous system.


2011 ◽  
Vol 29 (1) ◽  
pp. 205-226 ◽  
Author(s):  
Matthew J. Gallek ◽  
Leslie Ritter

In the past 25 years, remarkable progress has been made in our understanding of genomics and its influence on central nervous system diseases. In this chapter, common diseases of the central nervous system will be reviewed along with the genomics associated with these diseases. The diseases/injuries that will be investigated include neurovascular disorders such as ischemic stroke, hemorrhagic stroke, subarachnoid hemorrhage, and traumatic brain injury. This chapter will also explore Apolipoprotein E (APOE), a 299-aminoacid protein encoded by the APOE gene, and its associations with many of the previously named diseases. APOE was first tied to the risk of Alzheimer's disease and has since then been investigated in traumatic brain injury and hemorrhagic strokes. In addition, we will discuss the future of genomic research in central nervous system diseases.


1995 ◽  
Vol 15 (5) ◽  
pp. 860-864 ◽  
Author(s):  
Susan L. Kaczorowski ◽  
Joanne K. Schiding ◽  
Carol A. Toth ◽  
Patrick M. Kochanek

As part of the acute inflammatory response, neutrophils accumulate in the central nervous system after injury. Recently, a soluble human recombinant complement receptor (sCR1; BRL 55730; T Cell Sciences, Inc., Cambridge, MA, U.S.A.) has been developed that inhibits the activation of both the classical and the alternative pathways of complement. sCR1 attenuates the effects of the acute inflammatory response in several models of injury outside the central nervous system. The role of complement in traumatic brain injury, however, remains undefined. We hypothesized that treatment with sCR1 would attenuate neutrophil accumulation in the brain after cerebral trauma. Using a randomized, blinded protocol, 18 anesthetized Sprague–Dawley rats were pretreated with sCR1 or saline (control) at both 2 h and 2 min before trauma (weight drop) to the exposed right parietal cortex. A third dose of sCR1 (or saline) was given 6 h after trauma. Coronal brain sections centered on the site of trauma were obtained at 24 h after trauma and analyzed for myeloperoxidase (MPO) activity as a marker of neutrophil accumulation. Complete blood counts with differential were obtained before treatment with sCR1 and at 24 h after trauma. At 24 h after trauma, brain MPO activity was reduced by 41% in sCR1-treated rats compared with control rats [0.1599 ± 0.102 versus 0.27(2 ± 0.178 U/g (mean ± SD); p = 0.02]. The neutrophil count in peripheral blood increased approximately twofold in both groups. Neutrophil accumulation occurring in the brain after trauma is inhibited by sCR1 treatment. This suggests that complement activation is involved in the local inflammatory response to traumatic brain injury and plays an important role in neutrophil accumulation in the injured brain.


2021 ◽  
Vol 12 ◽  
Author(s):  
Di Wu ◽  
Jay Prakash P. Kumal ◽  
Xiaodi Lu ◽  
Yixuan Li ◽  
Dongsheng Mao ◽  
...  

An increasing number of studies have suggested that traumatic brain injury (TBI) is associated with some neurodegenerative diseases, including Alzheimer's disease (AD). Various aspects of the mechanism of TBI-induced AD have been elucidated. However, there are also studies opposing the view that TBI is one of the causes of AD. In the present study, we demonstrated that TBI exacerbated the disruption of hippocampal-dependent learning and memory, worsened the reductions in neuronal cell density and synapse formation, and aggravated the deposition of Aβ plaques in the hippocampi of APP/PS1 mice. We also found that TBI rapidly activated microglia in the central nervous system (CNS) and that this effect lasted for at least for 3 weeks. Furthermore, TBI boosted Aβ-related microglia-mediated neuroinflammation in the hippocampi of APP/PS1 mice and the transformation of microglia toward the proinflammatory phenotype. Therefore, our experiments suggest that TBI accelerates the onset of cognitive dysfunction and Alzheimer-like pathology in the APP/PS1 mouse model, at least partly by altering microglial reactions and polarization.


2010 ◽  
Vol 68 (5) ◽  
pp. 1059-1064 ◽  
Author(s):  
Vishal Bansal ◽  
Todd Costantini ◽  
Seok Yong Ryu ◽  
Carrie Peterson ◽  
William Loomis ◽  
...  

2020 ◽  
Vol 5 (6) ◽  
pp. 9-16
Author(s):  
S. A. Antonenko ◽  
◽  
A. N. Stoyanov ◽  
G. V. Gryshchenko ◽  
V. Z. Skorobrekh ◽  
...  

One of the most frequent and severe consequences of traumatic brain injury is post-traumatic epilepsy, which is the main identified cause of symptomatic epilepsy at a young age. Post-traumatic epilepsy develops in 11-20% of people who have had traumatic brain injury, its frequency and severity depends on the degree of damage to the central nervous system due to traumatic brain injury, the localization of the traumatic focus, the state of premorbid background, the presence of somatic and comorbid pathology, the state of the autonomic nervous system, etc. According to general population studies, severe traumatic brain injury increases the risk of post-traumatic epilepsy development by 29 times against mild, in which this indicator increases by 1.5 times. In children under 14 years old, the proportion of post-traumatic epilepsy can be up to 14%, while in people over 65 years old, this figure is 8%. The neurophysiological polymorphism of post-traumatic epilepsy is that traumatic brain injury is characterized by a predominantly focal nature of the development of the pathological process, but recently there have been many clinical and experimental confirmations of the presence of diffuse brain damage. These morphological and functional changes coexist and interact with each other with varying degrees of predominance. The work highlights the mechanisms of brain injury, including oxidative stress, leading to disruption of the functioning of all levels of the central nervous system. In the early period after traumatic brain injury, ischemic damage to the central nervous system dominates with the development of glutamate cascade, oxidative stress, etc. As a result of all pathological reactions, disintegration of the central nervous system develops with the development of basic neuropathological syndromes. In the intermediate period, with an unfavorable course of the pathological process, irritation syndromes are formed, in particular, epileptization of the brain with the possible appearance of repeated unprovoked paroxysms, as well as impairment of most neuropsychiatric functions due to excessive neuronal discharges. The formation of post-traumatic epilepsy has a delayed period of the emergence of a focus of epiactivity based on a cascade of morphofunctional "rewiring" of cortical and other networks, disorders of the functioning of the nervous system and depends on a number of "trigger" factors, incl. on the nature, localization, degree of damage, the state of the antiepileptic system and other factors stimulating the generator of hyperextension with the possible occurrence of secondary generators. At the same time, a pathological determinant is fully formed, which "epilepsizes" the brain. Conclusion. The issues of differentiation of post-traumatic epilepsy from other epileptic seizures, the dependence of post-traumatic epilepsy development on the severity of traumatic brain injury, the main risk factors for this type of epileptogenesis, as well as disorganization and damage to the antiepileptic system are considered. The existing wide range of seizures is described, incl. focal, taking into account the localization characteristic of traumatic brain injury


2021 ◽  
Vol 11 ◽  
Author(s):  
Sara Wojciechowski ◽  
Anaïs Virenque ◽  
Maria Vihma ◽  
Barbara Galbardi ◽  
Erin Jane Rooney ◽  
...  

RationaleThe recently discovered meningeal lymphatic vessels (mLVs) have been proposed to be the missing link between the immune and the central nervous system. The role of mLVs in modulating the neuro-immune response following a traumatic brain injury (TBI), however, has not been analyzed. Parenchymal T lymphocyte infiltration has been previously reported as part of secondary events after TBI, suggestive of an adaptive neuro-immune response. The phenotype of these cells has remained mostly uncharacterized. In this study, we identified subpopulations of T cells infiltrating the perilesional areas 30 days post-injury (an early-chronic time point). Furthermore, we analyzed how the lack of mLVs affects the magnitude and the type of T cell response in the brain after TBI.MethodsTBI was induced in K14-VEGFR3-Ig transgenic (TG) mice or in their littermate controls (WT; wild type), applying a controlled cortical impact (CCI). One month after TBI, T cells were isolated from cortical areas ipsilateral or contralateral to the trauma and from the spleen, then characterized by flow cytometry. Lesion size in each animal was evaluated by MRI.ResultsIn both WT and TG-CCI mice, we found a prominent T cell infiltration in the brain confined to the perilesional cortex and hippocampus. The majority of infiltrating T cells were cytotoxic CD8+ expressing a CD44hiCD69+ phenotype, suggesting that these are effector resident memory T cells. K14-VEGFR3-Ig mice showed a significant reduction of infiltrating CD4+ T lymphocytes, suggesting that mLVs could be involved in establishing a proper neuro-immune response. Extension of the lesion (measured as lesion volume from MRI) did not differ between the genotypes. Finally, TBI did not relate to alterations in peripheral circulating T cells, as assessed one month after injury.ConclusionsOur results are consistent with the hypothesis that mLVs are involved in the neuro-immune response after TBI. We also defined the resident memory CD8+ T cells as one of the main population activated within the brain after a traumatic injury.


ScienceRise ◽  
2020 ◽  
pp. 31-39
Author(s):  
Sergey Khudoley

The aim of the research. To study effects of activation and inhibition of the central cholinergic systems (CCS) in traumatic brain injury (TBI). Studied problem. To investigate the influence of the reactivity of the central cholinergic systems on the course of the acute period of traumatic brain injury, in an acute experiment on laboratory animals in vivo. The main scientific results. It was found that in the acute period of TBI (the first three days), both activation and blockade of CCS led to a decrease in mortality, which was statistically confirmed only for their activation. The control group was characterized by the progression of neurological deficit, which was realized due to motor disorders and reflex sphere. Upon activation of the CCS, the degree of neurological deficit was significantly less than in other groups, but, nevertheless, it increased from 48 hours after the injury, as regards behavioral and consciousness disorders. Inhibition of cholinergic systems led to a sharp increase in neurological deficit in all areas immediately after injury, to a greater extent due to reflex disorders. This, together with a high mortality rate, indicated a negative effect of the pharmacological shutdown of CCS in TBI. The area of practical use of the research results. The obtained results will allow a deeper study of the influence of the central cholinergic systems on the course and descent of TBI. To develop effective methods of pharmacological correction in the treatment of patients in the acute period of TBI. Innovative technological product: pathogenetically substantiated medical treatment of the acute period of traumatic brain injury, development of new methods of pharmacological neuroprotection for persons with a priori high risk of injury, development of effective options for reducing mortality and disability from TBI. Scope of the innovative technological product. The important role of CCS in the realization of the response of the central nervous system to TBI was established, and the possibility of using pharmacological stimulation of the central nervous system with cholinomimetics of the central type of action was justified.


Sign in / Sign up

Export Citation Format

Share Document